Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium

Status Withdrawn

Clinical Trial Summary

PQ-504a-001 (Fuchs Focus) is an open-label, single-dose, exploratory study to evaluate safety, tolerability, and corneal endothelium molecular biomarker(s) in subjects with Fuchs Endothelial Corneal Dystrophy with Trinucleotide Repeat Expansion in the TCF4 gene (FECD3).

Clinical Trial Description

PQ-504a-001 (Fuchs Focus) is an open-label, intra-subject-controlled study in subjects with FECD3 scheduled for Descemet's Membrane Endothelial Keratoplasty (DMEK) in both eyes or with concurrent, preemptive lens replacement surgery (LRS/DMEK), if indicated as part of routine clinical practice. Each subject will go through the following two parts in this study: • Part A without study drug administration: Part A of the study starts once LRS/DMEK of the first eye (hereafter called Eye 1) has been scheduled and subject eligibility has been confirmed. During the LRS/DMEK of Eye 1 corneal endothelium will be collected to assess the levels of selected molecular biomarkers. According to routine clinical practice, subjects will then be monitored for at least 4 weeks and up to approximately 6 months to evaluate recovery of Eye 1 prior to scheduling LRS/DMEK of the second eye (hereafter called Eye 2). The duration of the follow-up period also depends on the availability of cornea transplant material for Eye 2. Data generated during this part will serve as intra-subject control for data generated in Part B. • Part B with study drug administration: Part B of the study starts once LRS/DMEK in Eye 2 can be scheduled and subject eligibility for Part B has been confirmed. At least 4 weeks prior to the scheduled LRS/DMEK in Eye 2, the subject will receive a single dose of QR-504a administered intravitreally in Eye 2. During the LRS/DMEK in Eye 2 corneal endothelium will be collected for molecular biomarker assessments and subjects will continue to be followed for safety and tolerability for at least 12 months post-surgery (ie, at least 13 months post dosing). ;

Study Design

Related Conditions & MeSH terms

Corneal Diseases
Corneal Dystrophies, Hereditary
Fuchs Endothelial Corneal Dystrophy
Fuchs' Endothelial Dystrophy
Iridocorneal Endothelial Syndrome

Clinical Trial Details

NCT number	NCT05052554
Study type	Interventional
Source	ProQR Therapeutics
Contact
Status	Withdrawn
Phase	Phase 1
Start date	August 10, 2021
Completion date	April 12, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02291731` - Autologous Serum Eye Drops With Contact Lenses for Corneal Epithelial Defects	N/A
Completed	`NCT00810472` - Functional Antigen Matching in Corneal Transplantation	N/A
Completed	`NCT00029185` - Study of Dehydrex in Patients With Corneal Erosion	N/A
Enrolling by invitation	`NCT03436576` - Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye	Phase 3
Completed	`NCT02344732` - Effect of Systemic Oxygen on Corneal Epithelial Wound Healing in Diabetic Patients Undergoing Pars Plana Vitrectomy	N/A
Recruiting	`NCT06451172` - Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis	Early Phase 1
Not yet recruiting	`NCT05833737` - Corneal Findings in Patients Treated With Belantamab Mafodotin
Completed	`NCT04421300` - A Randomized Study of Smile Exercise for Dry Eye	N/A
Completed	`NCT00396188` - Screening Aid to Identify Corneas That May Have Pathologies or Other Conditions	Phase 1
Terminated	`NCT03029104` - Collagen Cross-Linking With Ultraviolet-A in Asymmetric Corneas	Phase 2
Completed	`NCT02348242` - Ocular Surface Disorders in Patients in Intensive Care Units, a Comparative Study of Three Preventive Approaches	N/A
Completed	`NCT00050466` - Dynamic Light Scattering and Keratoscopy for Corneal Examination	N/A
Recruiting	`NCT04164407` - Keratoconus, Corneal Diseases and Transplant Registry
Completed	`NCT00491439` - Using in Vivo Confocal Microscope to Evaluate the Corneal Wound Healing After Various Ocular Surgeries	N/A
Terminated	`NCT00447187` - Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects With FECD3 — Fuchs Focus

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms